

SEQUENCE LISTING

<110> Lion TCR Pte Ltd

<120> An HBV Antigen Specific Binding Molecules and Fragments Thereof

<130> 2016.P00486

<160> 39

<170> PatentIn version 3.5

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR 1a

<220>

<221> VARIANT

<222> (2)..(2)

<223> Xaa is either Ser or Ile

<400> 1

Asp Xaa Ser Ser Thr Tyr

1 5

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR2a

<400> 2

Ile Phe Ser Asn Met Asp Met

1 5

<210> 3

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR3a

<400> 3

Ala Glu Thr Leu Asp Asn Tyr Gly Gln Asn Phe Val
1 5 10

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1b

<400> 4

Asp Phe Gln Ala Thr Thr
1 5

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR2b

<400> 5

Ser Asn Glu Gly Ser Lys Ala
1 5

<210> 6
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR3b

<400> 6

Ser Ala Val Asp Arg Asp Glu Pro Phe His Ser Asn Gln Pro Gln His
1 5 10 15

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR1a

<400> 7
gacagctcct ccacctac 18

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR2a

<400> 8
attttttcaa atatggacat g 21

<210> 9
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR3a

<400> 9
gcagagacct tggataacta tggtcagaat ttgtc 36

<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR1b

<400> 10
gactttcagg ccacaact 18

<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR2b

<400> 11
tccaatgagg gctccaaggc c 21

<210> 12
<211> 48
<212> DNA

<213> Artificial Sequence

<220>

<223> CDR3b

<400> 12

agtgctgtag acagggatga acctttccat agcaatcagc cccagcat 48

<210> 13

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> CDR1a

<400> 13

gactcctcta gtacctac 18

<210> 14

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> CDR2a

<400> 14

atcttttcca acatggacat g 21

<210> 15

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> CDR3a

<400> 15

gccgagaccc tggacaacta cggccagaat ttcgtg 36

<210> 16

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> CDR1b

<400> 16

gattccagg ccaccaca 18

<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR2b

<400> 17
agcaacgaag gatcaaagc c 21

<210> 18
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> CDR3b

<400> 18
tcagcagtgg accgagatga acctttccac agcaaccagc cacagcat 48

<210> 19
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen C

<400> 19

Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5 10

<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen B

<400> 20

Leu Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5 10

<210> 21

<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen C

<400> 21

Ser Thr Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5 10 15

<210> 22
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen B

<400> 22

Ser Thr Thr Ser Gly Leu Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5 10 15

<210> 23
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen B and C

<400> 23

Val Leu Gln Ala Gly Phe Leu Leu Thr Arg Ile Leu Thr
1 5 10

<210> 24
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1a

<400> 24

Asp Ser Ser Ser Thr Tyr
1 5

<210> 25
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1a

<400> 25

Asp Ile Ser Ser Thr Tyr
1 5

<210> 26
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> HBVC/D Env 34-10

<400> 26

Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly
1 5 10

<210> 27
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen C

<400> 27

Ser Thr Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln
1 5 10

<210> 28
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen C

<400> 28

Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu
1 5 10 15

<210> 29
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen B

<400> 29

Leu Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu
1 5 10 15

<210> 30
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen C

<400> 30

Ser Thr Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala Gly
1 5 10 15

Phe Phe Leu Leu Thr Arg Ile Leu Thr
20 25

<210> 31
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> HBV Gen B

<400> 31

Ser Thr Thr Ser Gly Leu Leu Gly Pro Leu Leu Val Leu Gln Ala Gly
1 5 10 15

Phe Phe Leu Leu Thr Arg Ile Leu Thr
20 25

<210> 32
<211> 10
<212> PRT
<213> Artificial Sequence

<220>

<223> HBVB Env 34-1

<400> 32

Gly Leu Leu Gly Pro Leu Leu Val Leu Gln
1 5 10

<210> 33

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> HBVB Env 34-2

<400> 33

Gly Leu Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5 10

<210> 34

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HBVB 34-4

<400> 34

Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5

<210> 35

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> HBVB Env 34-5

<400> 35

Leu Leu Gly Pro Leu Leu Val Leu Gln Ala Gly
1 5 10

<210> 36

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> HBVB Env 34-6

<400> 36

Leu Gly Pro Leu Leu Val Leu Gln Ala Gly
1 5 10

<210> 37

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> HBVB Env 34-7

<400> 37

Gly Pro Leu Leu Val Leu Gln Ala Gly
1 5

<210> 38

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> HBVC/D Env 34-8

<400> 38

Gly Phe Leu Gly Pro Leu Leu Val Leu Gln Ala
1 5 10

<210> 39

<211> 170

<212> DNA

<213> Artificial Sequence

<220>

<223> pCR 4Blunt-TOPO

<400> 39

cacacaggaa acagctatga ccatgattac gccaaagctca gaattaaccc tcactaaagg 60

gactagtcct gcagggttaa acgaattcgc ccttaagggc gaattcgcgg ccgctaaatt 120

caattcgccc tatagtgagt cgtattacaa ttcactggcc gtcgttttac 170